PRESTIGE CONSUMER HEALTHCARE INC. Lessee, Operating Lease, Liability, to be Paid, after Year Five
PRESTIGE CONSUMER HEALTHCARE INC. (PBH) had Lessee, Operating Lease, Liability, to be Paid, after Year Five of $1.62 million as of 2026-03-31, per its 10-K filed 2026-05-14.
Financial Statements › Notes › Commitment and Contingencies › Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity
us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive · last filed 2026-05-14
- 2026-03-31: Lessee, Operating Lease, Liability, to be Paid, after Year Five $1.62M.
- 2025-03-31: Lessee, Operating Lease, Liability, to be Paid, after Year Five $1.15M.
- 2024-03-31: Lessee, Operating Lease, Liability, to be Paid, after Year Five $1.56M.
- 2023-03-31: Lessee, Operating Lease, Liability, to be Paid, after Year Five $257.00K.
| Period end | Lessee, Operating Lease, Liability, to be Paid, after Year Five |
|---|---|
| 2026-03-31 | $1.62M 10-K · filed 2026-05-14 |
| 2025-03-31 | $1.15M 10-K · filed 2025-05-09 |
| 2024-03-31 | $1.56M 10-K · filed 2024-05-15 |
| 2023-03-31 | $257.00K 10-K · filed 2023-05-05 |
| 2022-03-31 | $1.71M 10-K · filed 2022-05-06 |
| 2021-03-31 | $3.16M 10-K · filed 2021-05-07 |
| 2020-03-31 | $4.97M 10-K · filed 2020-05-08 |
| 2019-12-31 | $9.10M 10-Q · filed 2020-02-06 |
| 2019-09-30 | $9.10M 10-Q · filed 2019-10-31 |
| 2019-06-30 | $6.76M 10-Q · filed 2019-08-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |